InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8100
+0.0075 (0.93%)
At close: Jun 2, 2025, 4:00 PM
0.7808
-0.0292 (-3.60%)
After-hours: Jun 2, 2025, 7:56 PM EDT
InflaRx Revenue
InflaRx had revenue of 129.75K EUR in the twelve months ending March 31, 2025, up 30.90% year-over-year. In the year 2024, InflaRx had annual revenue of 165.79K with 162.79% growth.
Revenue (ttm)
129.75K EUR
Revenue Growth
+30.90%
P/S Ratio
386.46
Revenue / Employee
1,753 EUR
Employees
74
Market Cap
54.88M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IFRX News
- 5 days ago - InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
- 6 days ago - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewsWire
- 11 days ago - InflaRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewsWire
- 2 months ago - InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 3 months ago - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 3 months ago - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire